315 related articles for article (PubMed ID: 31606087)
1. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Osko JD; Christianson DW
Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
[TBL] [Abstract][Full Text] [Related]
2. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
3. Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
Osko JD; Christianson DW
Acta Crystallogr F Struct Biol Commun; 2020 Sep; 76(Pt 9):428-437. PubMed ID: 32880591
[TBL] [Abstract][Full Text] [Related]
4. Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
Osko JD; Christianson DW
Bioorg Med Chem Lett; 2020 Apr; 30(8):127023. PubMed ID: 32067866
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.
Porter NJ; Osko JD; Diedrich D; Kurz T; Hooker JM; Hansen FK; Christianson DW
J Med Chem; 2018 Sep; 61(17):8054-8060. PubMed ID: 30118224
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors.
Vögerl K; Ong N; Senger J; Herp D; Schmidtkunz K; Marek M; Müller M; Bartel K; Shaik TB; Porter NJ; Robaa D; Christianson DW; Romier C; Sippl W; Jung M; Bracher F
J Med Chem; 2019 Feb; 62(3):1138-1166. PubMed ID: 30645113
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6.
Osko JD; Christianson DW
Biochemistry; 2019 Dec; 58(49):4912-4924. PubMed ID: 31755702
[TBL] [Abstract][Full Text] [Related]
8. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
9. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Osko JD; Porter NJ; Narayana Reddy PA; Xiao YC; Rokka J; Jung M; Hooker JM; Salvino JM; Christianson DW
J Med Chem; 2020 Jan; 63(1):295-308. PubMed ID: 31793776
[TBL] [Abstract][Full Text] [Related]
10. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
[TBL] [Abstract][Full Text] [Related]
11. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Tavares MT; Kozikowski AP; Shen S
Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
13. Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.
Porter NJ; Wagner FF; Christianson DW
Biochemistry; 2018 Jul; 57(26):3916-3924. PubMed ID: 29775292
[TBL] [Abstract][Full Text] [Related]
14. Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a]pyridine-Capped Selective HDAC6 Inhibitors.
Mackwitz MKW; Hamacher A; Osko JD; Held J; Schöler A; Christianson DW; Kassack MU; Hansen FK
Org Lett; 2018 Jun; 20(11):3255-3258. PubMed ID: 29790770
[TBL] [Abstract][Full Text] [Related]
15. Fluorescence Polarization-Based Competition Assays to Evaluate Histone Deacetylase 6 Inhibitors.
Ashraf QF; Quilates EJ; Olaoye OO; de Araujo ED; Gunning PT
Methods Mol Biol; 2023; 2589():481-492. PubMed ID: 36255644
[TBL] [Abstract][Full Text] [Related]
16. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
17. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
18. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
19. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
20. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype.
Olaoye OO; Watson PR; Nawar N; Geletu M; Sedighi A; Bukhari S; Raouf YS; Manaswiyoungkul P; Erdogan F; Abdeldayem A; Cabral AD; Hassan MM; Toutah K; Shouksmith AE; Gawel JM; Israelian J; Radu TB; Kachhiyapatel N; de Araujo ED; Christianson DW; Gunning PT
J Med Chem; 2021 Mar; 64(5):2691-2704. PubMed ID: 33576627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]